In a bid to grow its immuno-oncology portfolio, Gilead Sciences has agreed to acquire Forty Seven, a clinical-stage company developing therapies targeting CD47. With the deal, Gilead gains access to Forty Seven’s lead candidate, magrolimab, a monoclonal antibody in Phase II development for the treatment of several cancers including myelodysplastic syndrome (MDS) and acute myeloid leukaemia. The deal comes three months after Forty Seven announced positive Phase I data for magrolimabin combination with azacitidine that showed an overall response rate of 92% in patients with higher-risk MDS.